drugset / Trial / NCT03323658
Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer
NaSequentialOpen-labelPrevention
Summary
This phase I trial studies the side effects and best dose of bexarotene in preventing breast cancer in patients at high risk for breast cancer. Bexarotene belongs to a class of drugs that are called rexinoids, and it may reduce the incidence of breast tumors.
Timeline
- Start
- 2018-06-15
- Primary completion
- 2021-08-03
- Completion
- 2022-03-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bexarotene | Small molecule | 10 mg | Topical |
| Subject | Bexarotene | Small molecule | 20 mg | Topical |